CD56-positive diffuse large B-cell lymphoma: Possible association with extranodal involvement and bcl-6 expression

Hematology

Volumn 15, Issue 3, 2010, Pages 157-161

  Gomyo, Hiroshi ^a   Kajimoto, Kazuyoshi ^a   Miyata, Yoshiharu ^a   Maeda, Akio ^a   Mizuno, Ishikazu ^a   Yamamoto, Katsuya ^b   Obayashi, Chiho ^a   Hanioka, Keisuke ^a   Murayama, Tohru ^a  

^a HYOGO CANCER CENTER   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

BCL 6; CD56; Diffuse large b cell lymphoma; Flow cytometry; NCAM

Indexed keywords

CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PROTEIN BCL 6; T LYMPHOCYTE ANTIGEN; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN;

ADULT; ARTICLE; B CELL LYMPHOMA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT RESPONSE; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ANTIGENS, CD56; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953602831     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X12583347113573     Document Type: Article

References (25)

1. Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 1987; 236: 799-806.
2. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983; 130: 2947-2951.
3. Weisberger J, Gorczyca W, Kinney MC. CD56-positive large B-cell lymphoma. Appl Immunohistochem MolMorphol 2006; 14: 369-374.
4. Muroi K, Omine K, Kuribara R et al. CD56 expression in B-cell lymphoma. Leuk Res 1998; 22: 201-202.
5. Otsuka M, Yakushijin Y, Hamada M, Hato T, Yasukawa M, Fujita S. Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance. Br J Haematol 2004; 127: 416-424.
6. Sekita T, Tamaru JI, Isobe K et al. Diffuse large B cell lymphoma expressing the natural killer cell marker CD56. Pathol Int 1999; 49: 752-758.
7. Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Grogan TM. Neural cell adhesion molecule-positive peripheral Tcell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood 1992; 79: 2432-2437.
8. Isobe Y, Sugimoto K, Takeuchi K et al. Neural cell adhesion molecule (CD56)-positive B-cell lymphoma. Eur J Haematol 2007; 79: 166-169.
9. Hammer RD, Vnencak-Jones CL, Manning SS, Glick AD, Kinney MC. Microvillous lymphomas are B-cell neoplasms that frequently express CD56. Mod Pathol 1998; 11: 239-246.
10. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
11. Gomyo H, Shimoyama M, Minagawa K et al. Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma. Haematologica 2003; 88: 1358-1365.
12. Palacio C, Acebedo G, Navarrete M et al. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas. Haematologica 2001; 86: 934-940.
13. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
14. van Imhoff GW, Boerma EJ, van der Holt B et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135-4142.
15. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
16. Offit K, Parsa NZ, Gaidano G et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993; 82: 2157-2162.
17. Taborelli M, Tibiletti MG, Martin V, Pozzi B, Bertoni F, Capella C. Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet Cytogenet 2006; 165: 106-113.
18. Nashelsky MB, Hess MM, Weisenburger DD et al. Cytogenetic abnormalities in B-immunoblastic lymphoma. Leuk Lymphoma 1994; 14: 415-420.
19. Lakkala T, Laasonen A, Franssila KO, Teerenhovi L, Knuutila S. Comparison of DNA and karyotype aneuploidy in malignant lymphomas. Am J Clin Pathol 1990; 94: 600-605.
20. Lopez-Guillermo A, Colomo L, Jimenez M et al. Diffuse large Bcell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23: 2797-2804.
21. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
22. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or RCHOP: a prospective correlative study. Blood 2006; 107: 4207-4213.
23. Inaba T, Shimazaki C, Sumikuma T et al. Expression of T-cellassociated antigens in B-cell non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 592-599.
24. Kaleem Z, White G, Zutter MM. Aberrant expression of T-cellassociated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2001; 115: 396-403.
25. Yamaguchi M, Seto M, Okamoto M et al. De novo CD5z diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-821.